LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mechanical Tissue Resuscitation Technology Shows Promise Preventing Cell Death Following Brain Injury

By LabMedica International staff writers
Posted on 24 Apr 2012
Print article
Scientists looking for an effective treatment for traumatic brain injury have found that the size and extent of damaged tissue can be reduced by using a new device to prevent cell death.

The research, the focus of a three-year, USD 1.5 million study funded by the US Department of Defense (Arlington, VA, USA), was published April 2012 in the journal Neurosurgery. The technology evaluated in lab rats, is called mechanical tissue resuscitation (MTR) and uses negative pressure to create an environment that fosters cell survival.

Louis C. Argenta, MD, and Michael Morykwas, PhD, professors from Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) department of plastic surgery and reconstructive surgery, and a multidisciplinary group of colleagues at Wake Forest Baptist, have more than 15 years of experience working with negative pressure devices to successfully treat wounds and burns. In this study, the team used MTR to remove fluid and other toxins that cause cell death from an injury site deep in the brain.

When the brain is injured by blunt force, explosion, or other trauma, the cells at the impact site are irreversibly damaged and they die. In the region surrounding the wound, injured cells release toxic compounds that cause the brain to swell and restrict blood flow and oxygen levels. This process results in more extensive cell death, which affects brain function. Dr. Argenta and his colleagues targeted these injured brain cells to determine if removing the fluid and toxic substances that lead to cell death could help improve survival of the damaged cells.

In the study, a bioengineered material matrix was positioned directly on the injured area in the brain and attached to a flexible tube connected to a microcomputer vacuum pump. The pump delivered a carefully controlled vacuum to the injured brain for 72 hours drawing fluid from the injury site.

The brain injuries treated with the device showed a considerable drop in brain swelling and release of toxic substances when compared to untreated injuries. Brains treated with the device revealed that over 50% more brain tissue could be preserved compared to nontreated animals. Behavioral function tests demonstrated that function was returned more rapidly in the MTR treated group.

“We have been very gratified by the results thus far. This study demonstrates that by working together a multidisciplinary group of researchers can develop new technology that could be used one day at the hospital bedside,” said Dr. Argenta.

The researchers are now assessing the same technology in stroke and brain hemorrhage models. “The Department of Defense has identified this as an area that is ripe for medical advancement,” said study coauthor Stephen B. Tatter, MD, PhD, professor of neurosurgery at Wake Forest Baptist Medical Center. “We believe it will soon be ready for a clinical trial.”

Related Links:

Wake Forest Baptist Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more